Lite Strategy (LITS) risk factors
Item 1A of every Lite Strategy, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors27 risks1 new3 dropped6 reworded
Lite Strategy now emphasizes its Litecoin Treasury Strategy and exposure to LTC price volatility alongside potential pre-clinical drug programs.
Filed Sep 28, 2026 - FY2025 10-K risk factors33 risks7 new11 dropped10 reworded
Lite Strategy added risks regarding its new Litecoin holding strategy and crypto asset market regulations.
Filed Sep 26, 2025 - FY2024 10-K risk factors37 risks
Lite Strategy is actively exploring strategic alternatives and has discontinued clinical programs like voruciclib and ME-344, implementing a workforce reduction. Significant risks include potential delisting from Nasdaq, activist pressure from major shareholders Anson Advisors and Cable Car Capital, and the need to secure additional capital if development resumes.
Filed Sep 19, 2024